수술 부위 감염 관리 시장 : 세계 예측(2026-2032년)

The Surgical Site Infection Control Market is projected to grow by USD 9.33 billion at a CAGR of 6.52% by 2032.

Surgical site infection control is a critical pillar of perioperative patient safety, antimicrobial stewardship, and hospital quality improvement. Surgical site infections are among the most preventable healthcare-associated infections, yet they remain clinically significant because they increase morbidity, prolong hospitalization, raise readmission risk, and intensify pressure on operating rooms, infection prevention teams, sterile processing departments, and post-acute care pathways. Effective surgical site infection prevention requires coordinated execution across preoperative screening, skin antisepsis, hair removal practices, antibiotic prophylaxis, sterile instrument reprocessing, environmental cleaning, normothermia maintenance, glycemic control, wound closure practices, and postoperative surveillance.

The current landscape is shaped by stricter infection prevention standards, growing surgical volumes in aging populations, higher acuity procedures, and rising concern over antimicrobial resistance. Hospitals and ambulatory surgery centers are prioritizing evidence-based surgical site infection prevention bundles aligned with recognized clinical guidance from public health agencies and professional societies. These bundles increasingly combine standardized perioperative infection control protocols with digital compliance monitoring, risk stratification, analytics-enabled surveillance, and real-time feedback for surgical teams. As surgical care shifts toward minimally invasive procedures, outpatient settings, and shorter lengths of stay, infection control strategies must extend beyond the operating room to include patient education, remote wound monitoring, and interoperable infection reporting.

Transformative Shifts in Surgical Site Infection Control

The surgical site infection control landscape is undergoing transformative shifts as healthcare systems move from reactive infection management to proactive, data-driven prevention. Traditional reliance on manual audits and retrospective chart review is being replaced by integrated surveillance workflows that connect electronic health records, microbiology data, pharmacy systems, operating room scheduling, sterilization records, and readmission indicators. This shift strengthens case detection, improves root-cause analysis, and supports faster intervention when infection trends emerge.

Another major change is the expansion of standardized surgical safety bundles. Evidence-based measures such as appropriate antimicrobial timing, weight-based dosing, intraoperative redosing, chlorhexidine-based skin preparation where clinically appropriate, nasal decolonization for selected high-risk patients, maintenance of perioperative normothermia, and glucose control are increasingly embedded into operating room checklists and perioperative pathways. At the same time, sterile processing quality is receiving greater attention due to the complexity of reusable surgical instruments and the need for validated cleaning, disinfection, sterilization, and traceability procedures.

The care setting is also changing. More procedures are being performed in ambulatory surgery centers and short-stay surgical units, requiring infection control programs that are scalable, auditable, and suitable for decentralized care delivery. Post-discharge surveillance has become more important because many surgical site infections are identified after patients leave the facility. This is driving adoption of patient-reported outcome tools, telehealth wound checks, digital photography protocols, and structured follow-up for high-risk surgeries.

Cumulative Impact of Artificial Intelligence on Infection Prevention

Artificial intelligence is creating cumulative impact across surgical site infection control by improving risk prediction, surveillance accuracy, workflow prioritization, and quality improvement feedback loops. Machine learning models can analyze structured and unstructured data from electronic health records, procedure type, comorbidities, prior colonization, antibiotic exposure, laboratory values, operating time, implant use, and postoperative encounters to help identify patients at elevated risk for surgical site infection. When implemented with clinical validation and governance, these tools can support targeted preoperative optimization, enhanced monitoring, and more efficient allocation of infection prevention resources.

AI-enabled natural language processing can strengthen infection surveillance by reviewing operative notes, wound documentation, microbiology reports, discharge summaries, and readmission records for signals that may be missed in manual review. Computer vision and image-analysis tools are also being explored to assist wound assessment, detect visual changes over time, and support remote postoperative triage. In sterile processing and operating room logistics, AI can help identify instrument reprocessing bottlenecks, predict case delays that may affect workflow discipline, and support traceability analytics for quality assurance.

However, AI in surgical site infection prevention must be deployed responsibly. Model performance can vary across populations, procedure types, documentation practices, and care settings. Effective use requires transparent validation, bias monitoring, clinician oversight, cybersecurity controls, and alignment with regulatory and ethical expectations. The most durable value emerges when AI complements infection prevention expertise rather than replacing it, enabling faster detection, more precise prevention bundles, and continuous improvement across the perioperative continuum.

Key Regional Insights for Surgical Site Infection Control

Asia-Pacific is experiencing heightened attention to surgical site infection control as expanding surgical capacity, rapid hospital modernization, and national patient safety initiatives increase demand for standardized perioperative infection prevention. Countries across the region are strengthening antimicrobial stewardship, sterilization practices, and hospital accreditation programs, while large surgical volumes make scalable surveillance and staff training essential. The region's diversity creates uneven implementation, with advanced digital hospitals adopting analytics-enabled surveillance while resource-constrained settings prioritize foundational measures such as hand hygiene, sterile technique, instrument reprocessing, and antibiotic prophylaxis compliance.

North America demonstrates mature adoption of surgical site infection prevention bundles supported by national quality reporting, infection surveillance networks, antimicrobial stewardship requirements, and strong hospital accreditation frameworks. The United States and Canada emphasize standardized measurement, surgical checklist integration, and post-discharge infection tracking, particularly for high-risk procedures involving implants, colorectal surgery, cardiothoracic surgery, orthopedic surgery, and obstetric procedures. Digital health integration and electronic health record-based analytics are increasingly central to infection prevention performance improvement.

Latin America is advancing surgical site infection control through hospital quality programs, infection prevention education, and broader antimicrobial resistance strategies. Implementation varies by country and facility type, with leading urban hospitals adopting structured surveillance and perioperative bundles while smaller or resource-limited facilities focus on essential infection prevention infrastructure. Public and private healthcare systems are prioritizing sterilization quality, antibiotic stewardship, and healthcare worker training to reduce preventable postoperative infections.

Europe benefits from strong public health coordination, established infection surveillance systems, and regional emphasis on antimicrobial resistance containment. European healthcare systems commonly integrate surgical site infection indicators into hospital quality management, with attention to perioperative antibiotic protocols, device-associated risk, sterile processing validation, and environmental hygiene. Cross-border guidance and national surveillance programs support benchmarking, although differences in healthcare financing, digital maturity, and reporting practices influence implementation.

The Middle East is strengthening surgical site infection prevention through hospital accreditation, medical tourism standards, investment in tertiary care infrastructure, and infection prevention workforce development. Gulf health systems are particularly focused on quality metrics, advanced operating room environments, and digital hospital transformation. Across the broader region, priorities include standardizing perioperative protocols, improving antimicrobial stewardship, and expanding surveillance capacity.

Africa faces a high-priority need for surgical site infection control because infection prevention infrastructure, sterilization capacity, antibiotic access, and surveillance systems remain variable across many settings. Surgical safety initiatives, workforce training, and low-cost evidence-based measures are central to improving outcomes. The region's infection control agenda increasingly emphasizes clean surgery, safe water and sanitation in healthcare facilities, proper instrument reprocessing, rational antibiotic use, and practical surveillance methods suitable for constrained environments.

Key Group Insights Across Healthcare and Economic Alliances

ASEAN countries are advancing surgical site infection control through healthcare modernization, infection prevention training, and growing adoption of hospital accreditation standards. Regional diversity remains substantial, with Singapore and other digitally mature systems emphasizing electronic surveillance, antimicrobial stewardship, and perioperative quality dashboards, while emerging healthcare systems focus on foundational prevention bundles, sterile processing capacity, and workforce education. Cross-border medical travel also reinforces the importance of consistent infection prevention protocols and transparent quality practices.

The GCC is characterized by strong investment in hospital infrastructure, accreditation-driven quality improvement, and digital health strategies that support surgical site infection prevention. Health systems in the group emphasize advanced operating room standards, infection surveillance, antimicrobial stewardship, and perioperative protocol compliance, particularly in tertiary and specialty care facilities. Medical tourism ambitions and public sector modernization are further reinforcing attention to measurable surgical safety outcomes.

The European Union benefits from coordinated public health policy, antimicrobial resistance action plans, and established healthcare-associated infection surveillance mechanisms. Surgical site infection control across the EU is supported by standardized reporting frameworks, clinical guidance, and hospital quality systems, although differences in national implementation, coding practices, and digital interoperability affect comparability. The EU's emphasis on patient safety, prudent antibiotic use, and evidence-based perioperative care continues to shape infection prevention strategies.

BRICS countries represent a broad range of surgical site infection control maturity, from highly advanced tertiary hospitals to facilities still strengthening core infection prevention infrastructure. Large patient populations, high surgical demand, and antimicrobial resistance concerns make prevention bundles, antibiotic stewardship, and scalable surveillance critical. Digital transformation in major hospital networks is supporting risk stratification and reporting, while public health priorities continue to emphasize basic infection prevention and safe surgical systems.

G7 countries generally have well-established infection prevention governance, robust hospital accreditation expectations, and advanced surgical safety programs. Their priorities increasingly include AI-supported surveillance, antimicrobial stewardship optimization, reusable instrument traceability, and post-discharge monitoring. As aging populations require more complex surgeries, G7 health systems are focusing on reducing preventable complications, improving perioperative pathway reliability, and integrating infection control data into broader value-based care initiatives.

NATO member countries include a wide range of healthcare system structures, but many share strong emphasis on surgical readiness, infection prevention standards, and resilient healthcare infrastructure. Surgical site infection control is relevant not only in civilian hospitals but also in military and emergency surgical environments where wound contamination risk, trauma care, and rapid deployment conditions require disciplined aseptic practices, sterilization logistics, antimicrobial protocols, and surveillance systems adaptable to varied care settings.

Key Country Insights Shaping Surgical Site Infection Prevention

The United States has a highly structured surgical site infection control environment supported by national healthcare-associated infection surveillance, hospital quality reporting, antimicrobial stewardship requirements, and strong perioperative safety standards. Facilities focus on procedure-specific prevention bundles, EHR-enabled surveillance, and readmission monitoring. Canada emphasizes patient safety, infection prevention accreditation, antimicrobial stewardship, and provincial surveillance approaches, with attention to standardized perioperative practices and post-discharge follow-up.

Mexico is strengthening surgical site infection control through hospital quality programs, infection prevention training, and efforts to improve antimicrobial stewardship, while implementation can vary between public and private facilities. Brazil places increasing emphasis on healthcare-associated infection surveillance, sterilization quality, and surgical safety programs, particularly in large hospitals and academic medical centers. The United Kingdom maintains mature infection prevention systems supported by national guidance, antimicrobial stewardship, and quality oversight, with surgical pathways increasingly integrating preoperative optimization and postoperative monitoring.

Germany's surgical site infection control landscape is supported by rigorous hospital hygiene standards, surveillance participation, and strong sterile processing practices. France prioritizes infection prevention governance, antibiotic stewardship, and structured surveillance, with attention to high-risk procedures and hospital quality indicators. Russia continues to develop infection control capabilities across a large and diverse healthcare system, with priorities including surveillance consistency, antimicrobial resistance management, and standardized perioperative protocols.

Italy and Spain both emphasize hospital infection prevention programs, antimicrobial stewardship, and surgical safety protocols, with ongoing focus on reducing healthcare-associated infections in high-volume public healthcare systems. China is advancing surgical site infection control through hospital modernization, quality accreditation, antimicrobial stewardship policies, and expanding digital health infrastructure, while large surgical volumes require scalable implementation. India faces a dual agenda of advanced infection prevention in leading tertiary hospitals and foundational improvements across broader healthcare settings, including sterile processing, antibiotic stewardship, and post-discharge surveillance.

Japan has a mature patient safety environment with strong attention to perioperative process discipline, antimicrobial stewardship, and quality improvement in surgical care. Australia emphasizes national safety standards, infection prevention accreditation, surveillance, and evidence-based perioperative bundles, supported by strong antimicrobial stewardship frameworks. South Korea combines advanced hospital digitalization, infection control programs, and quality assessment mechanisms to improve surgical site infection prevention, with growing focus on analytics, post-discharge surveillance, and standardized surgical pathways.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated surgical site infection control strategies that combine evidence-based clinical bundles, digital surveillance, workforce competency, and continuous quality improvement. The first priority is standardization: perioperative teams should align protocols for preoperative screening, skin antisepsis, antimicrobial prophylaxis, sterile technique, instrument reprocessing, temperature control, glucose management, and wound care with recognized clinical guidance and local epidemiology. Protocols should be embedded into surgical checklists, order sets, and operating room workflows to improve reliability.

Second, leaders should strengthen surveillance across the full episode of care. Because many infections present after discharge, organizations should connect inpatient records, outpatient visits, microbiology results, readmissions, patient-reported symptoms, and telehealth wound reviews. Third, antimicrobial stewardship should be tightly linked to surgical pathways to ensure appropriate selection, timing, dosing, redosing, and discontinuation of prophylactic antibiotics. Fourth, sterile processing departments should receive sustained investment in training, equipment validation, instrument traceability, and audit readiness.

Fifth, organizations should adopt AI and analytics cautiously but proactively. Predictive tools should be validated locally, monitored for bias, and integrated into clinician-led workflows. Finally, leadership should establish transparent performance dashboards, multidisciplinary case reviews, and feedback loops for surgeons, anesthesiologists, nurses, infection preventionists, pharmacists, environmental services, and sterile processing teams. The highest-performing programs treat surgical site infection control as a systemwide safety discipline rather than a single-department responsibility.

Research Methodology for Verified Infection Control Insights

The research methodology for surgical site infection control should be grounded in verified clinical evidence, public health guidance, peer-reviewed literature, hospital quality standards, infection surveillance frameworks, and regulatory requirements. A robust approach includes secondary research from recognized health authorities, infection prevention organizations, surgical societies, antimicrobial stewardship guidance, hospital accreditation standards, and published studies on surgical site infection prevention bundles, perioperative workflows, sterilization practices, and post-discharge surveillance.

Primary insights should be developed through structured interviews with infection preventionists, perioperative nurses, surgeons, anesthesiologists, pharmacists, sterile processing leaders, hospital epidemiologists, quality officers, and digital health specialists. Data triangulation is essential to compare clinical guidelines, real-world implementation patterns, regional healthcare infrastructure, and patient safety priorities. Evaluation criteria should include evidence strength, protocol feasibility, interoperability requirements, workforce implications, antimicrobial resistance relevance, and measurable quality outcomes.

To maintain analytical integrity, the methodology should exclude unsupported assumptions and avoid market sizing, market share, or forecasting. Findings should be validated against current infection prevention practices, recognized surveillance definitions, and regional healthcare policy developments. This approach ensures that strategic insights remain clinically relevant, operationally practical, and aligned with verified data-backed infection control priorities.

Conclusion: Advancing Safer Surgery Through Infection Prevention

Surgical site infection control is evolving into a digitally enabled, multidisciplinary, and outcomes-focused discipline that spans the entire surgical journey. The most effective programs integrate standardized prevention bundles, reliable sterile processing, antimicrobial stewardship, real-time surveillance, post-discharge monitoring, and continuous feedback to surgical teams. Regional and country-level differences in healthcare infrastructure, surveillance maturity, and workforce capacity shape implementation, but the core objective remains consistent: reducing preventable postoperative infections and improving patient safety.

Artificial intelligence, electronic surveillance, remote wound monitoring, and interoperable clinical data systems are strengthening the ability to identify risk, detect infections earlier, and target interventions. However, technology must be paired with strong governance, clinical validation, staff training, and adherence to evidence-based practice. Industry leaders that invest in protocol reliability, multidisciplinary accountability, and data-driven improvement will be best positioned to advance surgical safety, support antimicrobial resistance containment, and improve perioperative care quality across hospitals and ambulatory surgical settings.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Surgical Site Infection Control Market, by Product Type

• 7.1. Introduction
• 7.2. Antimicrobial Sutures
  • 7.2.1. Silver-Coated Sutures
  • 7.2.2. Triclosan-Coated Sutures
• 7.3. Negative Pressure Wound Therapy Devices
  • 7.3.1. Single-Use Systems
  • 7.3.2. Traditional Systems
• 7.4. Surgical Dressings
  • 7.4.1. Alginate Dressings
  • 7.4.2. Foam Dressings
  • 7.4.3. Hydrocolloid Dressings
• 7.5. Topical Antiseptics
  • 7.5.1. Alcohol-Based
  • 7.5.2. Chlorhexidine-Based
  • 7.5.3. Povidone-Iodine-Based

8. Surgical Site Infection Control Market, by Surgery Type

• 8.1. Introduction
• 8.2. Cardiovascular Surgery
  • 8.2.1. Coronary Artery Bypass
  • 8.2.2. Valve Replacement
• 8.3. General Surgery
  • 8.3.1. Abdominal Procedures
  • 8.3.2. Gastrointestinal Procedures
• 8.4. Obstetrics And Gynecology Surgery
  • 8.4.1. C Section
  • 8.4.2. Hysterectomy
• 8.5. Orthopedic Surgery
  • 8.5.1. Joint Replacement
  • 8.5.2. Spinal Surgery

9. Surgical Site Infection Control Market, by End User

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers
  • 9.2.1. Freestanding Centers
  • 9.2.2. Hospital Affiliated Centers
• 9.3. Clinics
  • 9.3.1. Outpatient Clinics
  • 9.3.2. Specialty Clinics
• 9.4. Hospitals
  • 9.4.1. Private Hospitals
  • 9.4.2. Public Hospitals

10. Surgical Site Infection Control Market, by Application

• 10.1. Introduction
• 10.2. Intraoperative Wound Irrigation
  • 10.2.1. Antibiotic Irrigation
  • 10.2.2. Saline Irrigation
• 10.3. Postoperative Wound Management
  • 10.3.1. Dressing Changes
  • 10.3.2. Wound Debridement
• 10.4. Preoperative Skin Preparation
  • 10.4.1. Chlorhexidine Preparation
  • 10.4.2. Povidone-Iodine Preparation

11. Surgical Site Infection Control Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Surgical Site Infection Control Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Surgical Site Infection Control Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. FPNV Positioning Matrix, 2025
• 14.3. Market Concentration Analysis, 2025
  • 14.3.1. Concentration Ratio (CR)
  • 14.3.2. Herfindahl Hirschman Index (HHI)
• 14.4. Recent Developments & Impact Analysis, 2025
• 14.5. Product Portfolio Analysis, 2025
• 14.6. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. 3M Company
• 15.2. American Polyfilm Inc
• 15.3. Ansell Limited
• 15.4. B Braun Melsungen AG
• 15.5. Becton Dickinson and Company
• 15.6. Belimed AG
• 15.7. BioMerieux SA
• 15.8. Cardinal Health
• 15.9. ConvaTec Group
• 15.10. Covalon Technologies Ltd
• 15.11. Destiny Pharma
• 15.12. Ecolab Inc
• 15.13. Eppendorf SE
• 15.14. Fortive Corporation
• 15.15. Getinge AB
• 15.16. Johnson and Johnson
• 15.17. Lac Mac Limited
• 15.18. Matachana Group
• 15.19. Medline Industries
• 15.20. Medtronic plc
• 15.21. Molnlycke Health Care AB
• 15.22. Pacon Manufacturing Corporation
• 15.23. Paul Hartmann AG
• 15.24. PolyPid
• 15.25. Reckitt Benckiser Group
• 15.26. Smith and Nephew plc
• 15.27. Sotera Health
• 15.28. STERIS plc
• 15.29. Stryker Corporation
• 15.30. Vomaris Innovations